|
1.
|
|
9 p, 267.6 KB |
VITAL phase 2 study : Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)
/
Feliu, Jaime (Hospital Universitario La Paz (Madrid)) ;
Garcia-Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ;
Capdevila, J (Vall d'Hebron Institut d'Oncologia) ;
Guasch, Inmaculada (Hospital Althaia Assistencial de Manresa) ;
Alonso-Orduña, Vícente (Hospital Universitario Miguel Servet (Saragossa)) ;
López-López, Carlos A. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Castañón, Carmen (Hospital Virgen Blanca) ;
Sevilla, Isabel Ñíguez (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cerezo, Laura (Hospital Universitario de la Princesa (Madrid)) ;
Conill, Carlos (Universitat de Barcelona) ;
Quintana Ángel, Begoña (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sánchez, María E. (Hospital Universitario La Paz (Madrid)) ;
Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ;
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Lopez-Gomez, Miriam (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)) ;
León, Ana Isabel (Hospital Universitario Fundacion Jimenez Diaz) ;
Caro, Monica (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fernandez, Teresa López (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Maurel, Joan (Universitat de Barcelona) ;
Universitat Autònoma de Barcelona
VITAL, a phase II single-arm study, aimed to evaluate efficacy and safety of panitumumab addition to 5-fluorouracil (5-FU), mitomycin-C (MMC) and radiotherapy (RT) in patients with localized squamous cell carcinoma of the anal canal (SCCAC). [...]
2020 -  10.1002/cam4.2722
Cancer Medicine, Vol. 9 Núm. 3 (january 2020) , p. 1008-1016
|
|
|
2.
|
|
11 p, 458.4 KB |
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
/
Yoshino, Takayuki (National Cancer Center Hospital East) ;
André, Thierry (Sorbonne University) ;
Kim, Tae Won (University of Ulsan) ;
Yong, Wei Peng (National University Cancer Institute) ;
Shiu, Kai-Keen (University College Hospital) ;
Jensen, Benny Vittrup (Herlev and Gentofte Hospital) ;
Jensen, Lars Henrik (University Hospital of Southern Denmark) ;
Punt, Cornelis J. A. (University Medical Center Utrecht) ;
Smith, Denis (Hôpital Haut-Lévêque) ;
García-Carbonero, Rocío (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Alcaide-Garcia, Julia (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Gibbs, Peter (Western Hospital) ;
de la Fouchardiere, Christelle (Centre Léon Bérard) ;
Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Le, Dung T. (Johns Hopkins Medicine) ;
Adachi, Noriaki (Merck (Estats Units d'Amèrica)) ;
Fogelman, David (Merck(Estats Units d'Amèrica)) ;
Marinello, Patricia (Merck (Estats Units d'Amèrica)) ;
Diaz, Luis A. (Memorial Sloan Kettering Cancer Center) ;
Universitat Autònoma de Barcelona
The phase 3 KEYNOTE-177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite-instability-high (MSI-H)/mismatch-repair-deficient (dMMR) metastatic colorectal cancer (mCRC). [...]
2022 - 10.1111/cas.15650
Cancer Science, Vol. 114 (december 2022) , p. 1026-1036
|
|
|
3.
|
|
9 p, 402.4 KB |
Gender influence on work satisfaction and leadership for medical oncologists : a survey of the Spanish Society of Medical Oncology (SEOM)
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Ayala de la Peña, Francisco (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron) ;
García Campelo, Rosario G. (Complexo Hospitalario Universitario) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
García Donas, J (Centro Integral Oncológico Clara Campal (CIOCC)) ;
González-del-Alba, Aránzazu (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
González-Flores, Encarnación (Hospital Universitario Virgen de las Nieves (Granada)) ;
Hidalgo, Julia (Hospital Lluis Alcanyís de Xativa) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Lescure, Álvaro (Hospital General Universitario de Elche) ;
Safont, María José (Consorcio Hospital General Universitario Valencia) ;
Santaballa, Ana (Hospital Universitari i Politècnic La Fe (València)) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Vera, Ruth (Complejo Hospitalario de Navarra) ;
Garrido, Pilar (Hospital Universitario Ramón y Cajal (Madrid))
Background: Women represent an increasing proportion of the oncology workforce; however, globally this does not translate into leadership roles, reflecting disparities in career opportunities between men and women. [...]
2021 - 10.1016/j.esmoop.2021.100048
ESMO open, Vol. 6 Núm. 2 (april 2021) , p. 100048
|
|
|
4.
|
|
9 p, 1.6 MB |
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
/
Trilla-Fuertes, Lucía (Biomedica Molecular Medicine (Madrid)) ;
Gámez-Pozo, Angelo (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
García-Carbonero, Rocío (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
G-Pastrián, Laura (Hospital Universitario La Paz (Madrid)) ;
Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ;
Peña, Cristina (Hospital Universitario La Paz (Madrid)) ;
López-Vacas, Rocío (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco) ;
Llorens, Carlos (Biotechvana SL (Madrid)) ;
Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ;
Conill, Carles (Hospital Clínic i Provincial de Barcelona) ;
Heredia Soto, Victoria (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Campos-Barros, Ángel (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Fresno Vara, Juan Ángel (Centro de Investigación Biomédica en Red de Cáncer) ;
Feliu, Jaime (Universidad Autónoma de Madrid) ;
Universitat Autònoma de Barcelona
Squamous cell carcinoma is the most frequent histologic type of anal carcinoma. The standard of care since the 1970s has been a combination of 5-fluorouracil, mitomycin C, and radiotherapy. This treatment is very effective in T1/T2 tumors (achieving complete regression in 80-90% of tumors). [...]
2021 - 10.1038/s41598-021-86966-w
Scientific reports, Vol. 11 (april 2021)
|
|
|
5.
|
|
25 p, 2.1 MB |
Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas
/
García-Carbonero, Rocío (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Matute Teresa, F. (Hospital Clínico San Carlos (Madrid)) ;
Mercader-Cidoncha, E. (Hospital General Universitario Gregorio Marañón) ;
Mitjavila-Casanovas, M. (Grupo de Trabajo de Endocrino de la SEMNIM, Madrid, Spain) ;
Robledo, Mercedes (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Tena, I. (Hospital Provincial. Medical Oncology Department) ;
Álvarez-Escolá, Cristina (Hospital Universitario La Paz (Madrid)) ;
Arístegui, M. (Hospital General Universitario Gregorio Marañón) ;
Bella-Cueto, Maria Rosa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Ferrer-Albiach, C. (Consorci Hospitalari Provincial de Castelló) ;
Hanzu, Felicia A (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla and the sympathetic/parasympathetic neural ganglia, respectively. The heterogeneity in its etiology makes PPGL diagnosis and treatment very complex. [...]
2021 - 10.1007/s12094-021-02622-9
Clinical & Translational Oncology, Vol. 23 (may 2021) , p. 1995-2019
|
|
|
6.
|
|
9 p, 1.3 MB |
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set
/
Grothey, Axel (Mayo Clinic) ;
Yoshino, Takayuki (National Cancer Center Hospital East) ;
Bodoky, Gyorgy (St László Hospital (Hongria)) ;
Ciuleanu, Tudor Eliade (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ;
García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ;
Muro, Kei (Aichi Cancer Center Hospital) ;
Mytelka, Daniel S. (Formerly of Eli Lilly and Company) ;
Li, Li (Eli Lilly and Company) ;
Lipkovich, Olga (Eli Lilly and Company) ;
Hsu, Yanzhi (Eli Lilly and Company) ;
Sashegyi, Andreas (Eli Lilly and Company) ;
Ferry, David (Eli Lilly and Company) ;
Nasroulah, Federico (Eli Lilly Argentina) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)
|
|
|
7.
|
|
16 p, 1003.6 KB |
Update of the recommendations for the determination of biomarkers in colorectal carcinoma : National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
/
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
García-Foncillas, Jesús (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Pérez-Segura, Pedro (Hospital Clínico San Carlos (Madrid)) ;
Salazar, R. (Centro de Investigación Biomédica en Red de Cáncer) ;
Vera, Ruth (Complejo Hospitalario de Navarra) ;
Ramón y Cajal, S. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hernández-Losa, J. (Hospital Universitari Vall d'Hebron) ;
Landolfi, Stefania (Vall d'Hebron Institut d'Oncologia) ;
Musulén, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ;
Navarro, S. (Hospital Clínic Universitari (València)) ;
Universitat Autònoma de Barcelona
In this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica-SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica-SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. [...]
2020 - 10.1007/s12094-020-02357-z
Clinical & Translational Oncology, Vol. 22 (may 2020) , p. 1976-1991
|
|
|
8.
|
|
8 p, 712.6 KB |
Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
/
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Portnoy, D. C. (The West Clinic, Memphis, USA) ;
Obermannová, R. (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ;
Bodoky, G. (St László Hospital (Hongria)) ;
Prausová, J. (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Cohn, A. L. (Rocky Mountain Cancer Center, LLP, Denver, USA) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Yamazaki, K. (Shizuoka Cancer Center, Shizuoka, Japan) ;
Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ;
Muro, K. (Aichi Cancer Center Hospital) ;
Kim, T. W. (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ;
Yamaguchi, K. (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ;
Grothey, A. (Mayo Clinic, Phoenix, USA) ;
O'Connor, J. (Instituto Alexander Fleming (Buenos Aires, Argentina)) ;
Taieb, Julien (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ;
Wijayawardana, S. R. (Eli Lilly and Company, Indianapolis, USA) ;
Hozak, Rebecca R (Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F. (Eli Lilly and Company, Buenos Aires, Argentina) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131
|
|
|
9.
|
|
7 p, 1.3 MB |
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
/
Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Pezet, Denis (Centre Hospitalier Universitaire) ;
Deplanque, Gael (Hôpital Riviera-Chablais) ;
Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ;
Trojan, Jorg (Goethe University Medical Center) ;
Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ;
Kozloff, Mark (Ingalls Memorial Hospital) ;
Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ;
Smith, Claire (formerly of Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ;
Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ;
Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ;
Blunt, Al (Advaxis, Inc) ;
Benhadji, Karim A. (Eli Lilly and Company) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Universitat Autònoma de Barcelona
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214
|
|
|
10.
|
|
8 p, 1.4 MB |
Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma
/
Trilla-Fuertes, Lucía (Biomedica Molecular Medicine (Madrid)) ;
Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ;
Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
G-Pastrián, Laura (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ;
Peña, Cristina (Hospital Universitario La Paz (Madrid)) ;
López-Vacas, Rocío (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Prado-Vázquez, Guillermo (Biomedica Molecular Medicine (Madrid)) ;
López-Camacho, Elena (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Zapater-Moros, Andrea (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Heredia Soto, Victoria (Hospital Universitario La Paz (Madrid)) ;
Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Conill, Carles (Hospital Clínic i Provincial de Barcelona) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Heath, Karen E. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ;
Llorens, Carlos (Biotechvana SL, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ;
Campos-Barros, Ángel (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Gámez-Pozo, Angelo (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Feliu, Jaime (Universidad Autónoma de Madrid) ;
Vara, Juan Ángel Fresno (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Anal squamous cell carcinoma (ASCC) is a rare neoplasm. Chemoradiotherapy is the standard of care, with no therapeutic advances achieved over the past three decades. Thus, a deeper molecular characterization of this disease is still necessary. [...]
2020 - 10.1016/j.tranon.2020.100778
Translational Oncology, Vol. 13 (may 2020)
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
